Market capitalization | KRW66.48t |
Enterprise Value | KRW66.50t |
P/E (TTM) P/E ratio | 63.16 |
EV/FCF (TTM) EV/FCF | 60.51 |
EV/Sales (TTM) EV/Sales | 15.24 |
P/S ratio (TTM) P/S ratio | 15.23 |
P/B ratio (TTM) P/B ratio | 6.28 |
Revenue growth (TTM) Revenue growth | 21.69% |
Revenue (TTM) Revenue | KRW4.36t |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
26 Analysts have issued a SAMSUNG BIOLOGICS forecast:
26 Analysts have issued a SAMSUNG BIOLOGICS forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4,364,392 4,364,392 |
22%
22%
|
|
Gross Profit | 2,108,959 2,108,959 |
12%
12%
|
|
EBITDA | 1,934,585 1,934,585 |
28%
28%
|
EBIT (Operating Income) EBIT | 1,344,356 1,344,356 |
25%
25%
|
Net Profit | 1,052,506 1,052,506 |
12%
12%
|
In millions KRW.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Head office | South Korea |
CEO | John Rim |
Employees | 4,425 |
Founded | 2011 |
Website | www.samsungbiologics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.